Table 1.
Baseline patient characteristics
| Characteristic | Panobinostat (N = 21) | Panobinostat and rituximab (N = 19) | Overall (N = 40) |
|---|---|---|---|
| Median age (range), y | 63.2 (30.9-78.6) | 57.2 (28.9-72.4) | 59.8 (28.9-78.6) |
| Female sex, n (%) | 9 (42.9) | 10 (52.6) | 19 (47.5) |
| ECOG performance status | |||
| 0 | 6 (29) | 7 (37) | 13 (33) |
| 1 | 15 (71) | 12 (63) | 27 (67) |
| Stage, n (%) | |||
| I/II | 6 (28) | 7 (37) | 13 (32.5) |
| III/IV | 15 (72) | 11 (58) | 26 (65) |
| Unknown | — | 1 (5) | 1 (2.5) |
| Transformed DLBCL | 5 (24) | 7 (37) | 12 (30) |
| IPI | |||
| 0 | 1 (5) | 1 (5) | 2 (5) |
| 1 | 4 (19) | 7 (37) | 11 (27.5) |
| 2 | 7 (33) | 4 (21) | 11 (27.5) |
| ≥3 | 9 (43) | 7 (37) | 16 (40) |
| Median number of prior therapies (range) | 2 (1-8) | 3 (2-9) | 3 (1-9) |
| Refractory to most recent therapy, n (%) | 12 (63) | 18 (86) | 30 (75) |
| Prior R-CHOP*, n (%) | 18 (86) | 17 (81) | 35 (87.5) |
| ASCT, n (%) | 6 (29) | 12 (63) | 18 (45) |
ASCT, autologous stem cell transplantation; IPI, international prognostic index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
*
All patients received prior rituximab-based chemoimmunotherapy.